# Sympatient

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sympatient

- Industry: Software
- Headquarters: Hamburg, Germany
- Website: www.sympatient.com
- Total disclosed funding: $9.7M
- Latest round: Series A (Jun 23, 2022)
- Investors on record: 2

## About

Sympatient GmbH specializes in innovative digital therapeutics, focusing on enhancing mental health care through the Invirto® therapy, a unique blend of virtual reality exposure treatment and cognitive behavioral therapy.Founded in 2017 in Hamburg, Germany, Sympatient GmbH develops digital therapeutics aimed at treating anxiety disorders. The company has raised EUR 7.500 mn in a SERIES A funding round led by Verve Ventures, with VIVUS Inc. also participating. The total amount raised by the company stands at EUR 7.500 mn with a current valuation of EUR 29.075 mn. The founders of Sympatient are Benedikt Reinke, Christian Angern, Jan Rösch, and Julian Angern.Sympatient offers innovative digital therapeutics (DTx), primarily centered around their flagship product, the Invirto® therapy. This is recognized as the first digital anxiety therapy that employs a combination of virtual reality exposure treatment with app-based cognitive behavioral therapy (CBT) for patients grappling with conditions such as agoraphobia, social phobia, or panic disorder. The Invirto® therapy empowers patients to engage in therapy from the comfort of their homes, thereby enhancing accessibility and convenience. The platform is designed to work in tandem with healthcare professionals, allowing therapists to utilize the DTx to optimize treatment outcomes, while also enabling patients to adopt self-directed therapy post-diagnosis. Sympatient's solutions are primarily targeted at the German healthcare market, collaborating with major health insurance companies, clinics, and patient associations to improve mental health care access.Sympatient generates revenue through a model that integrates partnerships with healthcare providers and insurance companies, allowing for reimbursement of their digital therapy offerings. The Invirto® therapy, as a recognized DiGA (Digital Health Application), is fully covered for 72 million insured individuals in Germany, which facilitates seamless access for patients and encourages broader adoption among therapists and clinics. Transactions typically occur through direct partnerships with healthcare entities, where Sympatient provides its digital solutions as part of a comprehensive patient care strategy. This includes a blended care approach that combines digital therapy with traditional in-person therapeutic sessions, thereby enhancing the overall treatment experience. Specific pricing plans for the services are structured to ensure they are accessible to a wide array of patients, reflecting the company's commitment to addressing the mental health crisis effectively.Sympatient GmbH raised an undisclosed amount of venture funding from new investor Kinled Holding. The funding will support the company's strategy for future growth, which includes the development of new therapeutic products and potential expansion into international markets. Specific geographic regions targeted for expansion have yet to be disclosed.

## Funding rounds

- Series A, Jun 23, 2022, $7.9M — VIVUS Inc., Verve Ventures
- Seed, May 28, 2020, $1.8M — VIVUS Inc., Verve Ventures

## Investors

- VIVUS Inc. — Seed, Series A
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Seed, Series A